Cheshire, CT, January 30, 2007 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York at 4:00 p.m. ET on Tuesday, February 6, 2007.<...  

CHESHIRE, CT, January 24, 2007 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Wachovia Securities 2007 Healthcare Conference in Boston at 9:00 a.m. ET on Wednesday, January 31, 2007.

An audio webcast of Dr. B...  

CHESHIRE, Conn., Dec. 9 -- Eculizumab, a novel monoclonal antibody investigational drug developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - News), appeared to be safe and well tolerated and provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in p...  

CHESHIRE, Conn., Nov. 29 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the BMO Capital Markets Focus on Healthcare Conference in New York City at 9:30 a.m. ET on Wednesday, December 6, 2006.

An audio webcast of...  

CHESHIRE, Conn., Nov. 21 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - News) today reported the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, which included 450,000 shares issued upon full exercise by the underwriters of an over-allotment option, all at a price to ...  

CHESHIRE, Conn., Nov. 14 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today its intention to publicly offer 2,500,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. The Company intends to grant the underwriters a 30-day opt...  

Cheshire, Conn., November 9, 2006 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that abstracts relating to Soliris(TM) (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). Each of these abstracts will be presented at the 2006 A...  

CHESHIRE, Conn., Nov. 1 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the third quarter ended September 30, 2006. For the third quarter, Alexion (the "Company") reported revenues of $0.3 million and a net loss of $31.9 million, resulting in a basic and dilute...  

CHESHIRE, Conn., Sept. 26 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that its wholly-owned subsidiary, Alexion Europe, has submitted a Market Authorization Application (MAA) to the European Medicines Evaluation Agency (EMEA) for Soliris(TM) (eculizumab) for the treatment of paroxysmal nocturnal hemog...  

CHESHIRE, Conn., September 20, 2006- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for its lead product candidate Soliris™ (eculizumab) as a treatment for patients diagnosed with paroxysmal nocturnal hemoglobinuria (PNH), a...